Swiss generic drugmaker Sandoz Group AG has created a global biosimilars unit to capitalize on drugs worth $650 billion losing patent protection over the next decade. This change will enable us to f… [+228 chars]
Source: Bloomberg
World
Sandoz Targets $650 Billion Opportunity With Biosimilars Unit
Swiss generic drugmaker Sandoz Group AG has created a global biosimilars unit to capitalize on drugs worth $650 billion losing patent protection over the next decade.
[ In-Article Advertisement Space ]
0 Comments
Sign in to join the conversation
No comments yet. Be the first!